Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05121337
Other study ID # 2021P000825
Secondary ID GEMS # 42359
Status Recruiting
Phase N/A
First received
Last updated
Start date September 30, 2022
Est. completion date September 30, 2025

Study information

Verified date November 2023
Source Beth Israel Deaconess Medical Center
Contact Stephen P Juraschek, MD, PhD
Phone 6177541416
Email sjurasch@bidmc.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

GoFresh is a randomized trial, testing the effects of a home-delivered DASH-patterned grocery intervention on blood pressure in Black adults, residing in Boston area urban food deserts.


Description:

Hypertension affects over half of Black adults in the United States - more than any other group - and diet is a principal determinant of disparities in hypertension among Black adults. While the DASH diet is a proven strategy for lowering blood pressure in Black adults, diet disparities are increasing in urban food deserts due to poor access and the high costs of healthy foods. This clinical trial will randomize 150 Black adults residing in Boston area urban food deserts to either: 1. 12 weeks of dietitian-assisted, DASH grocery delivery via an online, virtual grocery store at an amount sufficient to replace all Calorie needs of each participant, allowing for some sharing with family members or 2. Self-directed shopping with a monthly stipend over a 3-month period After the 12-week intervention phase, participants will undergo a 9-month observation phase. At 3-months after the intervention is complete the investigators will repeat in-person study assessments and perform qualitative interviews in a subset of the population to determine barriers and facilitators to intermediate-term maintenance of the intervention. At 9-months after the intervention, participants will participate in a phone visit designed to assess longer-term maintenance of the intervention.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date September 30, 2025
Est. primary completion date March 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility INCLUSION: - Self-reported/self-identified as Black or African American - Resting systolic blood pressure of 120 to <150 mm Hg and diastolic blood pressure <100 mm Hg - Residence in communities identified as Boston area food deserts: Brighton, Chelsea, Dorchester, East Boston, Everett, Hyde Park, Jamaica Plain, Malden, Mattapan, Revere, Roslindale, Roxbury, or Winthrop - Able to receive home-delivered groceries or pick them up at a convenient location and willing to eat only the groceries provided over a 12-week period - Have access to refrigeration, cooking appliances, and Wi-Fi/cellular service - Have access to mobile device or computer to be able to conduct grocery orders via video conference or by phone - Willing and able to complete required measurement procedures EXCLUSION: Laboratory Exclusions: - Serum potassium =5.0 mmol/L or <3.5 mmol/L - Estimated glomerular filtration rate (eGFR) <30 mL/min per 1.73 m^2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation - Hemoglobin A1c =6.5% Medication Exclusions: - Any use of medications that lower blood pressure or medications intended for hypertension treatment (including antihypertensives taken for non-hypertension purposes) within the last 6 months - Unstable doses (i.e. a change in the 2 months prior to screening or randomization) of the following: - Sodium-glucose co-transporter 2 (SGLT2) inhibitors - Stimulants - Inhaled or oral medications for asthma or chronic obstructive pulmonary disease (COPD) - Hormone replacement therapy or thyroid hormone - Weight-increasing psychotropic agents, including antipsychotic agents, lithium, and mirtazapine - Use of any of the following medications: - Potassium supplement, except if part of a multivitamin - Warfarin (Coumadin) - Chronic oral corticosteroid (intermittent use is okay) - Weight loss medications (including GLP-1 receptor agonists) - Unwillingness to keep same dose of vitamin, mineral, and botanical supplements - Any medication not compatible with participation as determined by the investigators Physical Exclusions: - Systolic blood pressure =150 mm Hg or diastolic blood pressure =100 mm Hg - Body weight >420 pounds - Arm circumference >50cm - Weight loss or gain of >5.0% of body weight during prior 2 months Medical History Exclusions: - Type 1 or Type 2 Diabetes defined as a hemoglobin A1c =6.5% or diabetes treatment - Active cardiovascular disease or any event in the prior 6 months, including coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), myocardial infarction (MI), cerebrovascular accident (CVA), or congestive heart failure (CHF) exacerbation requiring hospital admission - Cancer diagnosis or treatment in the last 2 years (non-melanoma skin cancer or localized breast or prostate or bladder cancer not requiring systemic therapy is acceptable) - Active inflammatory bowel disease, bowel resection, malabsorptive syndrome, pancreatitis (episode within past year), or history of bariatric surgery - Pregnancy or lactation or planned pregnancy - Any emergency department (ED) visit for asthma or chronic obstructive pulmonary disease (COPD) in the last 6 months - Any other serious illness or condition not compatible with participation as determined by the investigators Lifestyle and Other Exclusions: - Significant food allergies, preferences, intolerances, or dietary requirements that would interfere with diet adherence - Consumption of more than 14 alcoholic drinks per week or consumption of more than 6 drinks on one or more occasion per week - Active substance use disorder that would interfere with participation - Extreme food insecurity - Participation in or planning to start weight loss program - Current participation in another clinical trial that could interfere with the study protocol - Anticipated change in residence prior to the end of the study - Families with more than 6 adults at dinner time (children are considered to be half an adult) - Investigator discretion

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Dietitian-Assisted DASH groceries
The DASH ("Dietary Approaches to Stop Hypertension"), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages. Intervention Phase: This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size. Observation Phase: For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries.
Self-directed shopping
Intervention Phase: Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention. Observation Phase: For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend.

Locations

Country Name City State
United States Beth Israel Deaconess Medical Center - Clinical Research Center Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Beth Israel Deaconess Medical Center American Heart Association

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Qualitative Interviews The investigators will perform qualitative interviews in a subpopulation of both study assignments to assess for barriers and facilitators related to long-term maintenance of the intervention. 6 months after randomization
Other Short Form 12 Item Health Survey (SF-12) Assessment of global health-related quality of life Measured 3, 6, and 12 months after randomization
Other Grocery shopping and dining habits This is a modified version of the interviewer-administered SHoPPER (Study of Household Purchasing Patterns, Eating, and Recreation) instrument (French et al; PMID: 30808311) with some modifications to assess grocery shopping, meal preparation, and dining behaviors and habits. Measured 3, 6, and 12 months after randomization
Other Perceived Stress Scale 4 (PSS-4) An instrument used to assess participants' feelings about stress Measured 3, 6, and 12 months after randomization
Primary Seated, office-based, systolic blood pressure (intervention phase) In-person, measured with an automated oscillometric device that will perform 3 measurements. Measured 3 months after randomization
Secondary Seated, office-based, systolic blood pressure (observation phase) In-person, measured with an automated oscillometric device that will perform 3 measurements. Measured 6 months after randomization
Secondary Seated, office-based, diastolic blood pressure (intervention & observation phases) In-person, measured with an automated oscillometric device that will perform 3 measurements. Measured 3 and 6 months after randomization
Secondary Ambulatory blood pressure monitoring: wake-time systolic and diastolic blood pressure (intervention & observation phases) Ambulatory blood pressure monitoring with a mobile blood pressure device that will measure blood pressure over a 24-hour period. Measured 3 and 6 months after randomization
Secondary Body Mass Index (BMI) (intervention & observation phases) In-person, measurement based on height and weight. Height is measured via a stadiometer and weight is measured via calibrated scale. Measured 3 and 6 months after randomization
Secondary 24-hour urine potassium (intervention & observation phases) Collected at home after a clinic void over a 24-hour period Measured 3 and 6 months after randomization
Secondary 24-hour urine sodium (intervention & observation phases) Collected at home after a clinic void over a 24-hour period Measured 3 and 6 months after randomization
Secondary Hemoglobin A1c (intervention & observation phases) In-person blood collection; measure of glycemia over the preceding 3 months Measured 3 and 6 months after randomization
Secondary Lipids (intervention & observation phases) Measured in fasted serum specimens collected during phlebotomy. Includes total cholesterol, high density lipoprotein cholesterol, derived low density lipoprotein cholesterol, and triglycerides Measured 3 and 6 months after randomization
Secondary Serum potassium (intervention & observation phases) Measured in blood as part of a basic metabolic panel Measured 3 and 6 months after randomization
Secondary Serum creatinine (intervention & observation phases) Measured in blood as part of a basic metabolic panel Measured 3 and 6 months after randomization
Secondary Daily intake of fat, fruits, and vegetables (intervention & observation phases) Assessed via questionnaire in-person and via phone call; assessed via a validated food screener (Block et al; PMID: 10788730). Measured 3, 6, and 12 months after randomization
Secondary 24-hour dietary recall (intervention & observation phases) Assessed via questionnaire in-person using the Automated Self-Administered 24-Hour Dietary Recall (ASA24) Measured 3 and 6 months after randomization
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A
Completed NCT04303468 - Intervention With a GABA Supplement in Prediabetics N/A

External Links